

10

Name of Journal: World Journal of Gastroenterology

Manuscript NO: 46330

Manuscript Type: ORIGINAL ARTICLE

Prospective Study

Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma

Kuroda H *et al.* CEUS for response to lenvatinib in HCC

Hidekatsu Kuorda, Tamami Abe, Yudai Fujiwara, Takuya Okamoto, Miki Yonezawa, Hiroki Sato, Kei Endo, Takayoshi Oikawa, Kei Sawara, Yasuhiro Takikawa

Abstract

BACKGROUND

Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on contrast-enhanced ultrasound (CEUS) as early imaging biomarkers of lenvatinib efficacy.

AIM

To evaluate the potential of the early changes in the TIC of CEUS as early imaging biomarkers of lenvatinib efficacy in patients with unresectable HCC.

METHODS

We analyzed 20 consecutive patients with unresectable HCC treated with

Match Overview			 
1	Crossref 41 words Sugimoto, Katsutoshi, Fuminori Moriyasu, Kazuhiro Saito, Nicolas Rognin, Naohisa Kamiyama, Yoshihiro Furuichi, an	1%	
2	Internet 28 words crawled on 23-Oct-2018 www.spandidos-publications.com	1%	
3	Crossref 26 words "ECR 2014, Part B", Insights into Imaging, 2014	1%	
4	Internet 24 words crawled on 10-Jun-2018 erc.endocrinology-journals.org	1%	
5	Internet 17 words crawled on 14-Jul-2017 linknovate.com	1%	
6	Internet 17 words crawled on 11-Aug-2016 www.sciencedirect.com	1%	
7	Internet 17 words crawled on 15-Mar-2016 www.wjgnet.com	1%	
8	Internet 15 words crawled on 04-Dec-2018 spr.org.br	1%	
9	Crossref 14 words Kuroda, Hidekatsu, Keisuke Kakisaka, Takayoshi Oikawa, Mio Onodera, Yasuhiro Miyamoto, Kei Sawara, Ryujin End	<1%	
10	Internet 14 words	<1%	

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 20,000 条结果 (用时 0.51 秒)

Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin ...

[eisai.mediaroom.com/2018-10-09-Eisai-to-Present-LENVIMA-R-lenvatinib-...](https://www.eisai.mediaroom.com/2018-10-09-Eisai-to-Present-LENVIMA-R-lenvatinib-...) ▼ [翻译此页](#)

2018年10月9日 - New data on **tumor** growth rate and **lenvatinib efficacy** in ... Correlative analyses of serum **biomarkers** and **efficiency** outcomes for ... **Early** results of a Phase Ib/II study on the combination of eribulin and ... of **patients with unresectable hepatocellular carcinoma** (HCC) ... **Arterial** Thromboembolic Events.

Lenvatinib in Unresectable Hepatocellular Carcinoma - The ASCO Post

www.ascopost.com/.../lenvatinib-in-unresectable-hepatocellular-carcinoma/ ▼ [翻译此页](#)

2018年12月10日 - **Lenvatinib** in **Unresectable Hepatocellular Carcinoma** ... On August 16, 2018, **lenvatinib** (Lenvima) was approved for the **first-line** treatment of ... Supporting **Efficacy** Data ... **Patients** treated with **lenvatinib** should be regularly monitored for ... 79% had Child-Pugh A and Barcelona Clinic Liver **Cancer** (BCLC) ...

缺少字词: **Change** perfusion

Eisai to Present LENVIMA® (lenvatinib) and HALAVEN ... - PR Newswire

<https://www.prnewswire.com/.../eisai-to-present-lenvima-lenvatinib-and-hala...> ▼ [翻译此页](#)

2018年10月9日 - An oral presentation on **tumor** growth rate and **lenvatinib efficacy** in ... **Early** results of a Phase Ib/II study on the combination of eribulin and PEGPH20 ... Final analysis of serum **biomarkers** in **patients** (pts) from ... in **unresectable hepatocellular carcinoma** (uHCC) ... **Arterial** Thromboembolic Events. Among ...

Phase 2 study of lenvatinib in patients with advanced hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357473/> - [翻译此页](#)

作者: K Ikeda - 2017 - 被引用次数: 71 - [相关文章](#)

2016年10月4日 - The primary **efficacy** endpoint was time to progression (TTP) per modified Response ... Median body weight was lower in **patients** with an **early** (<30 days) dose ...

Keywords: **Hepatocellular carcinoma**, **Lenvatinib**, Tyrosine kinase inhibitor, a Waterfall

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 16,200 条结果 (用时 0.62 秒)

Clinical features of lenvatinib for unresectable hepatocellular ... - NCBI

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346240/> ▾ [翻译此页](#)作者: A Hiraoka - 2019 - 被引用次数: 1 - [相关文章](#)

We aimed to elucidate the therapeutic **efficacy** of LEN. ... For treatment of **unresectable hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors Characteristics of **patients** without a reduced **lenvatinib** dose starting and with ... glomerular filtration rate (eGFR) did not show significant **changes** within the **first** 4 weeks ...

缺少字词: **arterial perfusion biomarker**

Lenvatinib for the treatment of unresectable hepatocellular carcinoma ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362912/> - [翻译此页](#)作者: N Personeni - 2019 - [相关文章](#)

2019年1月31日 - Encouraging **efficacy** signals had already been reported for immune checkpoint ...

Keywords: **hepatocellular carcinoma**, **unresectable**, **first** line, ... A Phase I trial of **lenvatinib** in 20 **patients** with advanced **HCC** and Preplanned, exploratory, optional **biomarker** analyses on archival **tumor** tissues and serum ...

缺少字词: **arterial perfusion**

Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin ...

[eisai.mediaroom.com/2018-10-09-Eisai-to-Present-LENVIMA-R-lenvatinib-...](https://www.eisai.com/2018-10-09-Eisai-to-Present-LENVIMA-R-lenvatinib-...) ▾ [翻译此页](#)

2018年10月9日 - New data on **tumor** growth rate and **lenvatinib efficacy** in ... Correlative analyses of serum **biomarkers** and **efficiency** outcomes for ... **Early** results of a Phase Ib/II study on the combination of eribulin and ... of **patients with unresectable hepatocellular carcinoma (HCC)** ... **Arterial** Thromboembolic Events.

Systemic therapy for intermediate and advanced hepatocellular ...

[https://www.cancertreatmentreviews.com/article/S0305-7372\(18\)30075.../pd...](https://www.cancertreatmentreviews.com/article/S0305-7372(18)30075.../pd...) - [翻译此页](#)作者: JL Raoul - 2018 - 被引用次数: 13 - [相关文章](#)

The **hepatocellular carcinoma (HCC)** treatment landscape **changed** a decade ago, with ... further positive phase 3 studies emerging in the **first** line (**lenvatinib** ... clinical **biomarkers** for sorafenib **efficacy**. ... subgroups of **patients with unresectable HCC**: intermediate- (BCLC ... **Cancer** Treatment Reviews 68 (2018) 16–24.

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 4,040 条结果 (用时 0.48 秒)

Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin ...

eisai.mediaroom.com/2018-10-09-Eisai-to-Present-LENVIMA-R-lenvatinib-... - 翻译此页

2018年10月9日 - An oral presentation on **tumor** growth rate and **lenvatinib efficacy** in ... **Early** results of a Phase Ib/II study on the combination of eribulin and PEGPH20 ... Final analysis of serum **biomarkers** in **patients** (pts) from ... in **unresectable hepatocellular carcinoma** (uHCC) ... **Arterial** Thromboembolic Events. Among ...

Lenvatinib versus sorafenib in first-line treatment of patients with ...

<https://www.ncbi.nlm.nih.gov/pubmed/29433850> - 翻译此页

作者: M Kudo - 2018 - 被引用次数: 239 - 相关文章

2018年3月24日 - (8)National **Cancer** Center Korea, Goyang-si, South Korea. ... sorafenib as a **first-line** treatment for **unresectable hepatocellular carcinoma**. ... The **efficacy** analysis followed the intention-to-treat principle, and only **patients** who ...

缺少字词: ~~Change~~ arterial perfusion biomarker

Lenvatinib for the treatment of unresectable hepatocellular carcinoma ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362912/> - 翻译此页

作者: N Personeni - 2019 - 相关文章

2019年1月31日 - Encouraging **efficacy** signals had already been reported for immune checkpoint ...

Keywords: **hepatocellular carcinoma**, **unresectable**, **first line**, ... A Phase I trial of **lenvatinib** in 20 **patients** with advanced HCC and Preplanned, exploratory, optional **biomarker** analyses on archival **tumor** tissues and serum ...

缺少字词: arterial perfusion

A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX ...

clincancerres.aacrjournals.org/.../early/.../1078-0432.CCR-18-0847.full-text... - 翻译此页

2018年9月6日 - **Patients** with Advanced **Hepatocellular Carcinoma** (HCC) ... PURPOSE: Sorafenib is a standard **first-line** treatment for advanced ... **Biomarker** analysis showed significant **changes** ... **lenvatinib** demonstrated non-inferiority¹¹. ... transiently "normalize" the **tumor** vasculature and increase blood **perfusion**.

A Phase II and Biomarker Study of Sorafenib Combined with Modified ...

clincancerres.aacrjournals.org/.../early/.../1078-0432.CCR-18-0847.full-text... - 翻译此页

combination of sorafenib with modified (m)FOLFOX in the **first-line** systemic treatment of **Patients**